Prognostic factors of metastatic myxoid liposarcoma

BMC Cancer

Hiroshi Kobayashi¹  Hideo Morioka²  Naofumi Asano²  Robert Nakayama²  Hirotaka Kawano³  Yusuke Shinoda⁴  Eisuke Kobayashi⁵  Shintaro Iwata⁵  Tomoaki Mori⁵  Akira Kawai⁵  Tohru Hiruma⁶  Tsukasa Yonemoto⁷  Takeshi Ishii⁷ 

[1] Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo;Department of Orthopaedic Surgery, Keio University School of Medicine;Department of Orthopaedic Surgery, Teikyo University School of Medicine;Department of Rehabilitation Medicine, The University of Tokyo Hospital;Division of Musculoskeletal Oncology, National Cancer Center Hospital;Division of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center;Division of Orthopaedic Surgery, Chiba Cancer Center;

关键词: Myxoid liposarcoma;    Metastasis;    Prognostic factor;   

DOI  :  10.1186/s12885-020-07384-1

来源: DOAJ

【 摘 要 】

Abstract Background Myxoid liposarcoma (MLS) has the tendency to metastasize extrapulmonary. Although prognostic factors at the initial diagnosis of MLS have been reported, those at diagnosis of metastasis remain unclear. The purpose of this study was to investigate the prognostic factors for disease-specific survival at the initial diagnosis of metastasis. Methods This retrospective observational study was conducted at three cancer centers and two university hospitals in Japan. Of 274 MLS patients pathologically diagnosed between 2001 and 2015, 48 metastatic patients were examined. Results Lung metastases were detected in nine patients (18.8%) and extrapulmonary metastases in 45 (93.8%). Interval from primary diagnosis to the first metastasis was significantly shorter in patients with lung metastases than without (p = 0.007). Median disease-specific survival after diagnosis of metastases was 52.5 months in all patients. In multivariable analysis, liver metastasis (hazard ratio (HR), 2.71 [95% confidence interval (CI), 1.00–7.09]) and no evidence of disease (NED) achieved by radical treatment (resection with or without radiation therapy, or radiation therapy ≥60 Gy) or semi-radical (radiation therapy ≥40 Gy) treatment were significantly related to survival (HR, 0.36; 95%CI [0.13–0.95]). The number of metastases (odds ratio (OR), 0.44; 95%CI [0.25–0.78]) and abdominal/retroperitoneal metastases (OR, 0.09; 95%CI [0.008–0.95]) were the significant inhibitory factors of achieving NED. Conclusions This is the first study to statistically demonstrate the importance of achieving NED with surgical resection or radiation therapy for longer survival in metastatic MLS patients. As number of metastases was a significant factor for achieving NED, early detection of metastases might be important.

【 授权许可】

Unknown